BACKGROUND: Hepatocellular carcinoma (HCC) has a high mortality rate, and early detection of HCC improves patient survival. However, the molecular diagnostic markers for early HCC have not been fully elucidated. The aim of this study was to identify novel diagnostic markers for HCC. METHODS: Serum protein profiles of 45 hepatitis C virus infection (HCV)-related HCC patients (HCV-HCC) were compared to 42 HCV-related chronic liver disease patients without HCC (HCV-CLD) and 21 healthy volunteers using the ProteinChip SELDI system. One of the identified proteins was evaluated as a diagnostic marker for HCC in patients with HCV. RESULTS: Five protein peaks (4067, 4470, 7564, 7929, and 8130 m/z) had p-values less than 1 x 10(-7) and were significantly increased in the sera of HCV-HCC patients compared to HCV-CLD patients and healthy volunteers. Among these proteins, an 8130 m/z peak was the most differentially expressed and identified as the complement component 3a (C3a) fragment. For HCV-HCC and HCV-CLD, the relative intensity of this C3a fragment had the best area under the ROC curve [0.70], followed by des-gamma-carboxy prothrombin (DCP) [0.68], lectin-bound alpha fetoprotein (AFP-L3) [0.58] and AFP [0.53] for HCC. A combined analysis of the C3a fragment, AFP and DCP led to a 98% positive identification rate. In addition, the measurable C3a fragment in some HCC patients was not only significantly higher in the year of HCC onset compared to the pre-onset year, but also decreased after treatment. CONCLUSIONS: The 8130 m/z C3a fragment is a potential marker for the early detection of HCV-related HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) has a high mortality rate, and early detection of HCC improves patient survival. However, the molecular diagnostic markers for early HCC have not been fully elucidated. The aim of this study was to identify novel diagnostic markers for HCC. METHODS: Serum protein profiles of 45 hepatitis C virus infection (HCV)-related HCC patients (HCV-HCC) were compared to 42 HCV-related chronic liver diseasepatients without HCC (HCV-CLD) and 21 healthy volunteers using the ProteinChip SELDI system. One of the identified proteins was evaluated as a diagnostic marker for HCC in patients with HCV. RESULTS: Five protein peaks (4067, 4470, 7564, 7929, and 8130 m/z) had p-values less than 1 x 10(-7) and were significantly increased in the sera of HCV-HCC patients compared to HCV-CLDpatients and healthy volunteers. Among these proteins, an 8130 m/z peak was the most differentially expressed and identified as the complement component 3a (C3a) fragment. For HCV-HCC and HCV-CLD, the relative intensity of this C3a fragment had the best area under the ROC curve [0.70], followed by des-gamma-carboxy prothrombin (DCP) [0.68], lectin-bound alpha fetoprotein (AFP-L3) [0.58] and AFP [0.53] for HCC. A combined analysis of the C3a fragment, AFP and DCP led to a 98% positive identification rate. In addition, the measurable C3a fragment in some HCC patients was not only significantly higher in the year of HCC onset compared to the pre-onset year, but also decreased after treatment. CONCLUSIONS: The 8130 m/z C3a fragment is a potential marker for the early detection of HCV-related HCC.
Authors: Jens K Habermann; Uwe J Roblick; Brian T Luke; Darue A Prieto; William J J Finlay; Vladimir N Podust; John M Roman; Elisabeth Oevermann; Thomas Schiedeck; Nils Homann; Michael Duchrow; Thomas P Conrads; Timothy D Veenstra; Stanley K Burt; Hans-Peter Bruch; Gert Auer; Thomas Ried Journal: Gastroenterology Date: 2006-10 Impact factor: 22.682
Authors: M Ishii; H Gama; N Chida; Y Ueno; H Shinzawa; T Takagi; T Toyota; T Takahashi; R Kasukawa Journal: Am J Gastroenterol Date: 2000-04 Impact factor: 10.864
Authors: Laura F Steel; Donna Shumpert; Michael Trotter; Steven H Seeholzer; Alison A Evans; W Thomas London; Raymond Dwek; Timothy M Block Journal: Proteomics Date: 2003-05 Impact factor: 3.984
Authors: V V Khien; H V Mao; T T Chinh; P T Ha; M H Bang; B V Lac; T V Hop; N A Tuan; L V Don; K Taketa; S Satomura Journal: Int J Biol Markers Date: 2001 Apr-Jun Impact factor: 3.248
Authors: D G Ward; N Suggett; Y Cheng; W Wei; H Johnson; L J Billingham; T Ismail; M J O Wakelam; P J Johnson; A Martin Journal: Br J Cancer Date: 2006-06-06 Impact factor: 7.640
Authors: Jennifer Laskowski; Brandon Renner; Matthew C Pickering; Natalie J Serkova; Peter M Smith-Jones; Eric T Clambey; Raphael A Nemenoff; Joshua M Thurman Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: Caralee J Schaefer; Karl Kossen; Sharlene R Lim; Jiing-Huey Lin; Lin Pan; Williamson Bradford; Patrick F Smith; Scott D Seiwert Journal: Antimicrob Agents Chemother Date: 2011-04-18 Impact factor: 5.191
Authors: Asim Ejaz; Eike Steinmann; Zoltán Bánki; Sana Khalid; Susanne Lengauer; Corinne Wilhelm; Heinz Zoller; Anna Schloegl; Joerg Steinmann; Elena Grabski; Michael Kleines; Thomas Pietschmann; Heribert Stoiber Journal: PLoS One Date: 2012-09-25 Impact factor: 3.240
Authors: Cristiana C Garcia; Wynne Weston-Davies; Remo C Russo; Luciana P Tavares; Milene A Rachid; José C Alves-Filho; Alexandre V Machado; Bernhard Ryffel; Miles A Nunn; Mauro M Teixeira Journal: PLoS One Date: 2013-05-16 Impact factor: 3.240